idarubicin has been researched along with arsenic trioxide in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 14 (58.33) | 24.3611 |
| 2020's | 6 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, T; Imanaka, T; Ishii, K; Komatsu, H; Nakamura, F; Ono, Y; Sawada, H; Tanaka, Y | 1 |
| Au, WY; Chim, CS; Kwong, YL; Liang, R; Pang, A; Suen, C | 1 |
| Campbell, LJ; Catalano, A; Dawson, MA; Iland, H; Opat, S; Schwarer, A; Somana, K | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Blinder, R; Chang, P; Galinsky, I; Ho, VT; Housman, E; Kesari, S; Lane, SW; Mullally, A; Stone, RM | 1 |
| Andrews, C; Baer, MR; Barcos, M; Baumann, H; Block, AW; Ford, LA; Nowak, NJ; Sait, SN; Tighe, S; Wang, ES; Wetzler, M | 1 |
| Anderson, LD; Collins, RH; Kirk, A; Levitt, D; Naina, HV; Scaglioni, PP; Vusirikala, M | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Bashford, J; Bradstock, K; Browett, P; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C | 1 |
| Park, JH | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Iacoboni, G; Montesinos, P; Sanz, MA | 1 |
| Iland, HJ; Seymour, JF; Wei, A | 1 |
| Bowen, D; Burnett, AK; Clark, RE; Friis, L; Grech, A; Grimwade, D; Hills, RK; Hunter, A; Jones, G; Kell, J; Khwaja, A; Knapper, S; Lok, J; McMullin, MF; Morgan, YG; Russell, NH | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-De León, A; González-Leal, XJ; Gutiérrez-Aguirre, H; Jaime-Pérez, JC; Pinzón-Uresti, MA | 1 |
| Carcelero San Martín, E; Creus Baró, N; Riu Viladoms, G | 1 |
| Chan, AM; Mascarenhas, J; Rhee, JY; Tallman, MS; Tremblay, D | 1 |
| Chan, SY; Dang, CC; Guan, YK; Lau, NS | 1 |
| Chen, X; Guo, J; Jiang, L; Lei, P; Liu, Z; Ma, R; Shi, J; Yang, J; Yang, S; Yuan, X; Zang, Y; Zhang, L; Zhang, Y; Zhu, X; Zhu, Z | 1 |
| He, J; Wang, L; Yan, X | 1 |
| Su, YZ; Tao, HF; Xu, LW | 1 |
| Mao, Y; Tang, F; Xu, X; Zhu, X | 1 |
| Ahn, MJ; Bae, SH; Bang, SM; Cho, EK; Choi, JH; Chong, SY; Hyun, MS; Jo, DY; Kim, B; Kim, BS; Kim, CS; Kim, DY; Kim, H; Kim, HJ; Kim, HS; Kim, I; Kim, SH; Kwon, H; Lee, JH; Lee, KH; Lee, MH; Lee, WS; Min, YJ; Moon, HN; Mun, YC; Nam, SH; Oh, D; Park, JH; Park, KT; Park, SY; Park, YH; Ryoo, HM; Seo, JJ; Seong, CM; Yoon, HJ; Yoon, SS; Zang, DY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
7 review(s) available for idarubicin and arsenic trioxide
| Article | Year |
|---|---|
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
Conventional induction and post-remission therapy in APL: have we arrived?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Mitoxantrone; Multicenter Studies as Topic; Oxides; Remission Induction; Tretinoin | 2014 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Hydroxyurea; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Platelet Transfusion; Practice Guidelines as Topic; Remission Induction; Risk Assessment; Thioguanine; Treatment Outcome; Tretinoin | 2014 |
Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review.
Topics: Aged; Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Drug Therapy, Combination; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Myoclonus; Remission Induction; Steroids; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin; Withholding Treatment | 2019 |
Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Asian People; Consolidation Chemotherapy; Cytarabine; Decitabine; Drug Therapy, Combination; Female; Hospitalization; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Treatment Outcome; Tretinoin | 2020 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for idarubicin and arsenic trioxide
| Article | Year |
|---|---|
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Down-Regulation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; STAT3 Transcription Factor | 2011 |
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome; Tretinoin; Young Adult | 2012 |
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Denmark; Female; Humans; Idarubicin; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; New Zealand; Oncogene Proteins, Fusion; Oxides; Quality of Life; Real-Time Polymerase Chain Reaction; Time Factors; Treatment Outcome; Tretinoin; United Kingdom; Young Adult | 2015 |
14 other study(ies) available for idarubicin and arsenic trioxide
| Article | Year |
|---|---|
[Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Pleural Effusion; Remission Induction; Treatment Outcome; Tretinoin | 2000 |
Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Evaluation; Drug Synergism; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Pilot Projects; Prospective Studies; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Treatment Outcome | 2001 |
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Base Sequence; Bone Marrow; Chromosome Aberrations; Clinical Trials as Topic; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; DNA Mutational Analysis; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mutant Chimeric Proteins; Neoplasm Proteins; Oxides; Receptors, Retinoic Acid; Registries; Remission Induction; Retinoic Acid Receptor alpha; RNA, Messenger; Sequence Deletion; Tretinoin | 2007 |
CNS relapse in acute promyeloctyic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Brain Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cranial Irradiation; Cytarabine; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 2010 |
Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Bone Marrow; Bone Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Mercaptopurine; Methotrexate; Oxides; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma, Myeloid; Soft Tissue Neoplasms; Tetrahydronaphthalenes; Tretinoin | 2011 |
ATRA plus arsenic gets another "A" in APL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2012 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Oxides; Proportional Hazards Models; Treatment Outcome; Tretinoin; Young Adult | 2015 |
Severe myopericarditis following induction therapy with idarubicin and transretinoic acid in a patient with acute promyelocytic leukemia.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cardiovascular Agents; Chest Pain; Drug Substitution; Echocardiography; Electrocardiography; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Myocarditis; Pericarditis; Remission Induction; Tretinoin | 2018 |
Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Pregnancy; Recurrence; Tretinoin; Young Adult | 2020 |
Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2020 |
All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mutation; Prognosis; Tretinoin; Young Adult | 2021 |
Alternate application of all-trans-retinoic acid and arsenic trioxide combined with idarubicin/daunorubicin in treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Cohort Studies; Daunorubicin; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Prospective Studies; Tretinoin | 2022 |
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2022 |